The latest expansion builds on a $650M investment announced in 2025, reinforcing Puerto Rico’s role in U.S. biomanufacturing.

Amgen’s Expansion Reinforces Puerto Rico’s Role in U.S. Biomanufacturing

Amgen’s latest expansion in Puerto Rico marks a significant milestone for the island’s life sciences sector.

With a new $300 million expansion at its manufacturing facility in Juncos, building on the $650 million investment announced in September 2025, Amgen’s recent investment in Puerto Rico now totals nearly $1 billion.

For one of the world's leading biotechnology companies, this level of sustained investment reflects long-term confidence in Puerto Rico as a critical hub for U.S. biomanufacturing. It also underscores a broader reality: companies are scaling in Puerto Rico because it already delivers at global standards.

A Strategic Investment in Puerto Rico’s Manufacturing Capabilities

Amgen’s Puerto Rico operations have been a cornerstone of its global manufacturing network since 1992.

The company’s Juncos facility is one of the largest biologics manufacturing sites in the world, producing medicines distributed to more than 60 countries.

This latest $300 million investment will enhance advanced manufacturing capabilities, support next-generation technologies, and strengthen production capacity within the United States.

Strengthening U.S. Supply Chains Through Puerto Rico

Amgen’s expansion aligns with a broader trend: increasing investment in U.S.-based manufacturing to improve supply chain resilience.

As Robert A. Bradway, Chairman and Chief Executive Officer at Amgen, stated in the company’s official announcement, “By growing our operations in Puerto Rico, we are ensuring patients have access to the medicines they need, investing in the long-term strength of our domestic supply chain and supporting American jobs.”

Puerto Rico plays a unique role in U.S. manufacturing and supply chain strategy. As a U.S. jurisdiction with decades of pharmaceutical manufacturing experience, the island enables companies to scale operations within a well-established regulatory and operational framework.

For companies seeking to expand or reshore manufacturing, Puerto Rico provides both speed-to-market and proven reliability.

Why Biomanufacturing Leaders Choose Puerto Rico

Puerto Rico continues to attract investment from global life sciences companies due to its strong industrial foundation.

Key advantages include:

• More than 60 years of pharmaceutical and biotechnology manufacturing experience
• A highly skilled, bilingual workforce
• World-class infrastructure for regulated industries
• A robust ecosystem of global biopharma companies

As Sebastián Negrón Reichard, Secretary of the Puerto Rico Department of Economic Development and Commerce, noted, “Amgen’s additional $300 million commitment in Juncos is a powerful signal that the future of American biomanufacturing is being built here.”

These strengths have positioned Puerto Rico as one of the leading biomanufacturing hubs in the United States.

Investment Momentum in Puerto Rico’s Life Sciences Sector

Amgen’s nearly $1 billion commitment highlights a broader trend: companies are expanding where they already see success.

Rather than building new operations from the ground up, global manufacturers are scaling within established ecosystems that offer reliability, talent, and infrastructure.

Puerto Rico continues to stand out as a proven platform for growth in U.S. biomanufacturing.

Conozca más

Explore why leading life sciences companies continue to invest in Puerto Rico.